Navigation Links
ChemoCentryx to Present at The 9th World Congress on Inflammation in Tokyo, Japan
Date:7/8/2009

MOUNTAIN VIEW, Calif., July 8 /PRNewswire/ -- ChemoCentryx, Inc. today announced that Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer, will give a keynote lecture at The 9th World Congress on Inflammation in Tokyo, Japan. Dr. Schall's lecture titled, "Treating Inflammation by Inhibition of Chemokine Receptors: Practical Requirements and Efficacy of CCR9 Antagonism in Inflammatory Bowel Disease" will be given on Thursday, July 9, 2009 at 9:00 am local time.

"It is a privilege to have been invited to speak at this prestigious gathering of thought leaders involved in the search for innovative treatments in inflammatory disease," said Thomas J. Schall, Ph.D., ChemoCentryx's President and Chief Executive Officer. "With recent regulatory approvals and clinical trial successes of chemokine-based therapeutics, this underscores the enthusiasm and promise of developing drugs that selectively inhibit specific chemokine and chemoattractant receptors in the treatment of inflammatory diseases."

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, als
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
2. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
3. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
4. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Los Angeles, CA (PRWEB) May 24, 2013 ... is to present the 3rd Annual EB-5 Investment Summit: ... 2013. The Dealmakers Conference will focus on exploring alternative ... provide the latest market, legal and economic information, and ... legal professionals within the EB-5 industry. , "Our ...
(Date:5/24/2013)... 24, 2013 Dwell Media LLC ... Huff as Executive Vice President of Digital for Dwell ... which represented a large portion of Yahoo's global media ... Dwell develops a fully-integrated commerce unit to launch in ... monetizing digital content for leading firms in Silicon Valley. ...
(Date:5/24/2013)... 2013 Mike Stoler believes that there ... business people in New York. That’s why he ... on CUNY TV. And that’s why he invited ... Associates, LLP (ENTA)—the largest single specialty practice in the ... allergy and audiology specialists and sub-specialists service communities throughout ...
(Date:5/24/2013)... 24 (HealthDay News) -- Low-income, minority parents have ... and are more open to vaccinating their daughters ... small new study contends. Conversely, white, middle-class ... for their daughters, according to researchers from the ... Americans will get an HPV-related cancer each year, ...
(Date:5/24/2013)... the National Institutes of Health, Stevens Johnson Syndrome (SJS) is ... skin and mucous membranes. SJS occurs most commonly in ... In the early stages SJS presents flu-like symptoms, including ... affects the mucous membranes such as the eyes, mouth (lips ... causes conjunctivitis (pink eye). Inflammation of the mouth causes ...
Breaking Medicine News(10 mins):Health News:Brian Su Organizes 3rd Annual EB-5 Investment Conference in Long Beach, California 2Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3
... UCSF Medical Center patients, behind the scenes a family of ... new automated hospital pharmacy, believed to be the nation,s most ... and track medications with the goal of improving patient safety. ... 350,000 doses of medication prepared during the system,s recent phase ...
... tumor growth, and naturally mounts an anti-cancer defense. Dendritic ... present them to T cells, and those "primed" T ... cells. In recent years, researchers have attempted to capitalize ... namely, by generating a pool of tumor antigen-pulsed DCs ...
... Fla. (Mar. 07, 2011) Transplanting stem ... menstrual blood cells may offer future therapeutic benefit ... amyotrophic lateral sclerosis (ALS), says a team of ... Department of Neurosurgery and Brain Repair and collaborators ...
... By Steven Reinberg HealthDay Reporter , SUNDAY, March ... day offer a safe way to detect Down syndrome during ... blood test identified a gene mutation associated with Down syndrome ... "Down syndrome is a common birth defect, with one Down ...
... aging adults soon will face decisions about where and how ... including nursing homes and assisted-living facilities, are costly and require ... researchers have found that a new strategy for long-term care ... health outcomes. Adults want to remain healthy and ...
... easy? Then why didn,t anyone think of it a long ... at the right time," says Annette Rttger, physicist at the ... her scientific team managed to do something that was previously ... the measurement of short-lived radioactive thoron. Thoron measuring instruments from ...
Cached Medicine News:Health News:New UCSF robotic pharmacy aims to improve patient safety 2Health News:New UCSF robotic pharmacy aims to improve patient safety 3Health News:Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders 2Health News:Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders 3Health News:Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders 4Health News:Noninvasive Test May Identify Down Syndrome Early On 2Health News:Aging in place preserves seniors' independence, reduces care costs, MU researchers find 2Health News:Accurate measurement of radioactive thoron possible at last 2
(Date:5/24/2013)... 24, 2013  Sinovac Biotech Ltd. (NASDAQ: ... products in China , announced ... of Sinovac, obtained the Certificate of Good Manufacturing ... China State and Food Administration (CFDA) for its ... and its Changping filing and packaging facility. The ...
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
Breaking Medicine Technology:Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
... a world-leading developer, manufacturer and marketer of innovative medical ... following a review of current conditions in the credit ... secured term loans originally entered into on December 22, ... developer and marketer of innovative medical technologies. With four ...
... March 17, 2011 Pharmaceutics International Inc. (Pii), ... announced the appointment of Rampurna Prasad Gullapalli as ... is responsible for providing strategic scientific and technical ... and novel drug delivery technologies for Pii,s contract ...
Cached Medicine Technology:ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 2ConvaTec Healthcare Postpones Plans To Refinance Secured Term Loans 3Pharmaceutics International Inc. (Pii) Announces Appointment of Rampurna Prasad Gullapalli, Ph.D. as Vice President of Drug Delivery Technologies 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: